Skin cancers

Low relapse risk after stopping PD-1 inhibitor therapy in melanoma

The risk of relapse is low in patients with advanced melanoma who have achieved complete remission (CR) on PD-1 inhibitors and subsequently elect to discontinue treatment. An international study of 185 patients including Australians who discontinued treatment with either pembrolizumab or nivolumab – without indications such as disease progression or treatment-limiting toxicity – found overall ...

Already a member?

Login to keep reading.

© 2021 the limbic